GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 16:35:09 19/07/2024 BST 5-day change 1st Jan Change
1,522 GBX -0.49% Intraday chart for GSK plc +0.36% +4.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Close Lower Friday; Inflation Expectations Unchanged in ECB Survey MT
GSK's Marketing Authorization Application for Blenrep Combinations Accepted for Review in EU MT
GSK: marketing authorization from the EMA CF
Market hiccup: LSE glitch leaves traders hanging, FTSE 100 stutters Our Logo
GSK's Multiple Myeloma Combination Therapies Accepted for Review in EU MT
Stocks suffer on underwhelming local data AN
GSK drug for multiple myeloma accepted for European regulatory review AN
GSK: BLENREP (BELANTAMAB MAFODOTIN) COMBINATIONS IN MULTIPLE MYE… RE
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
EU court criticizes Commission over handling of COVID vaccine contracts RE
Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue MT
National Advisory Committee On Immunization Recommends RSV Vaccines, Including Arexvy, For Older Adult Populations RE
GSK: RSV VACCINATION RECOMMENDED FOR CONSIDERATION BY ADULTS AGE… RE
EQT Unit Invests in Biotechnology Company Asceneuron MT
Second malaria vaccine launched in Ivory Coast in new milestone RE
GSK: ViiH Healthcare to present its advances in HIV CF
GSK to Move Global Headquarters in London MT
GSK moves to new global headquarters in return to central London AN
European Equities Close Higher Thursday; UK GDP Grows More Than Expected MT
GSK: first shipments of flu vaccines to the USA CF
GSK Begins Shipping Flu Vaccines Flulaval, Fluarix MT
GSK: EXPECTS TO DISTRIBUTE OVER 36 MLN DOSES OF ITS TRIVALENT IN… RE
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season CI
GSK : Deutsche Bank reiterates its Buy rating ZD
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births RE
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.22 GBP
Average target price
19.88 GBP
Spread / Average Target
+30.57%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation